Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 8/20 | 0.47 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.46 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29656742 | 1.00 | P2RY14 (0.47) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7570192 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7541384 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7549022 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7569083 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7568905 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7541741 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7568791 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL7568898 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 | |
| SCHEMBL28582954 | 0.98 | P2RY14 (0.49) | P2RY14B4GALT1P2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119894521-A | Use of hypoxia-activated compounds for the preparation of a medicament for the treatment of cancer patients | 深圳艾欣达伟医药科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119384281-A | Methods of treating cancer using TH-302 single agents or in combination with PARP inhibitors | 深圳艾欣达伟医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118240821-A | SiRNA for specifically inhibiting PARG gene expression, and modifier, conjugate and application thereof | 四川大学华西医院 | 2024-06-25 | — | — | CN | disclosed |
| CN-113755414-B | Recombinant microorganism for producing uridine and method for producing uridine | 苏州华赛生物工程技术有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-116745410-A | Genetically engineered bacteria capable of producing cytokinins with isoprenoid side chains | 阿西耶斯生物公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116083487-A | Methods and compositions for treating genetic conditions | 桑格摩生物治疗股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2023074687-A1 | METHOD FOR MEASURING PYROPHOSPHORIC ACID OR PHOSPHORIBOSYL PYROPHOSPHATE, MEASUREMENT COMPOSITION AND REAGENT KIT FOR MEASURING SAME, AND AMPLIFICATION METHOD THEREOF | 旭化成ファーマ株式会社 | 2023-05-04 | — | — | WO | disclosed |
| CN-115552239-A | Liquid chromatography-based detection and quantification of phosphate prodrugs and active metabolites thereof | 沃特世科技公司 | 2022-12-30 | — | — | CN | disclosed |
| WO-2022202952-A1 | MODIFIED NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE | 三菱ケミカル株式会社 | 2022-09-29 | — | — | WO | disclosed |
| US-11261453-B2 | Cells expressing apolipoprotein E and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-03-01 | — | — | US | disclosed |
| CN-109843899-A | The poly-nuclear glycosyl polyribosylribitol phosphate derivative of the synthesis of stabilization hydrolysis as the vaccine to haemophilus influenzae type b | 马克斯·普朗克科学促进学会 | 2019-06-04 | — | — | CN | disclosed |
| WO-2017158132-A1 | MICROBIAL PRODUCTION OF NICOTINIC ACID RIBOSIDE | DSM IP ASSETS B.V. (NL) | 2017-09-21 | — | — | WO | disclosed |
| US-20160251665-A1 | CELLS EXPRESSING APOLIPOPROTEIN E AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-09-01 | — | — | US | disclosed |
| US-8311790-B2 | Reverse engineering genome-scale metabolic network reconstructions for organisms with incomplete genome annotation and developing constraints using proton flux states and numerically-determined sub-systems | UNIVERSITY OF DELAWARE (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2206501-A2 | HMGA binding nucleic acids | Noxxon Pharma AG (DE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090259451-A1 | REVERSE ENGINEERING GENOME-SCALE METABOLIC NETWORK RECONSTRUCTIONS FOR ORGANISMS WITH INCOMPLETE GENOME ANNOTATION AND DEVELOPING CONSTRAINTS USING PROTON FLUX STATES AND NUMERICALLY-DETERMINED SUB-SYSTEMS | UNIVERSITY OF DELAWARE (US) | 2009-10-15 | — | — | US | disclosed |
| WO-1998015655-A1 | PRIMER EXTENSION REACTION UTILIZING A COSUBSTRATE-ENZYME PAIR FOR CONSUMING PYROPHOSPHATE | THE PERKIN-ELMER CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| CN-1106460-A | Method for prepn. of adenosin- and cytidine-diphosphates | INST OF BIOLOG PHYSICS C A S (CN) | 1995-08-09 | — | — | CN | disclosed |
| CN-1049156-A | Indenoindole compounds | UNIV BATH (GB) | 1991-02-13 | — | — | CN | disclosed |